559 related articles for article (PubMed ID: 35222404)
1. Immunotherapy in Lung Cancer: Current Landscape and Future Directions.
Mamdani H; Matosevic S; Khalid AB; Durm G; Jalal SI
Front Immunol; 2022; 13():823618. PubMed ID: 35222404
[TBL] [Abstract][Full Text] [Related]
2. The landscape of immune checkpoint inhibitor therapy in advanced lung cancer.
Wang C; Li J; Zhang Q; Wu J; Xiao Y; Song L; Gong H; Li Y
BMC Cancer; 2021 Aug; 21(1):968. PubMed ID: 34454455
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy for early-stage non-small cell lung cancer: A system review.
Gao J; Zhang C; Wei Z; Ye X
J Cancer Res Ther; 2023 Aug; 19(4):849-865. PubMed ID: 37675709
[TBL] [Abstract][Full Text] [Related]
4. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
Xia L; Liu Y; Wang Y
Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
[TBL] [Abstract][Full Text] [Related]
5. [Therapeutic efficacy analysis of immunotherapy in small cell lung cancer].
Zhong J; Zheng QW; Zhao J; Wang ZP; Wu MN; Zhuo ML; Wang YY; Li JJ; Yang X; Chen HX; An TT
Zhonghua Zhong Liu Za Zhi; 2020 Sep; 42(9):771-776. PubMed ID: 32988161
[No Abstract] [Full Text] [Related]
6. Treatment patterns and outcomes of immunotherapy in extensive-stage small-cell lung cancer based on real-world practice.
Yang Y; Ai X; Xu H; Yang G; Yang L; Hao X; Yang K; Mi Y; Wang G; Zhang S; Lei S; Wang Y
Thorac Cancer; 2022 Dec; 13(23):3295-3303. PubMed ID: 36218023
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapy for small cell lung cancer: established applications and novel approaches.
Scott SC; Hann CL
Clin Adv Hematol Oncol; 2021 Oct; 19(10):654-663. PubMed ID: 34637432
[TBL] [Abstract][Full Text] [Related]
8. Immune Checkpoint Inhibitors and Chemoradiation for Limited-Stage Small Cell Lung Cancer.
Schlick B; Shields MD; Marin-Acevedo JA; Patel I; Pellini B
Curr Treat Options Oncol; 2022 Aug; 23(8):1104-1120. PubMed ID: 35716328
[TBL] [Abstract][Full Text] [Related]
9. Small-Cell Lung Cancer-An Update on Targeted and Immunotherapies.
McNamee N; da Silva IP; Nagrial A; Gao B
Int J Mol Sci; 2023 May; 24(9):. PubMed ID: 37175833
[TBL] [Abstract][Full Text] [Related]
10. The immunotherapeutic landscape in non-small cell lung cancer and its surgical horizons.
Rhodin KE; Rucker AJ; Ready NE; D'Amico TA; Antonia SJ
J Thorac Cardiovasc Surg; 2020 Apr; 159(4):1616-1623. PubMed ID: 31836182
[TBL] [Abstract][Full Text] [Related]
11. Immune Checkpoint Inhibitors (ICIs) in Non-Small Cell Lung Cancer (NSCLC).
Yoneda K; Imanishi N; Ichiki Y; Tanaka F
J UOEH; 2018; 40(2):173-189. PubMed ID: 29925736
[TBL] [Abstract][Full Text] [Related]
12. Emerging drugs for small cell lung cancer: a focused review on immune checkpoint inhibitors.
Reddy HG; Qin A; Kalemkerian GP
Expert Opin Emerg Drugs; 2020 Sep; 25(3):353-366. PubMed ID: 32683991
[TBL] [Abstract][Full Text] [Related]
13. The new era of immune checkpoint inhibition and target therapy in early-stage non-small cell lung cancer. A review of the literature.
Catania C; Muthusamy B; Spitaleri G; Del Signore E; Pennell NA
Clin Lung Cancer; 2022 Mar; 23(2):108-115. PubMed ID: 34952792
[TBL] [Abstract][Full Text] [Related]
14. Current state of the art and future perspectives with immunotherapy in the management of small cell lung cancer.
Rijavec E; Genova C; Biello F; Rossi G; Indini A; Grossi F
Expert Rev Respir Med; 2021 Nov; 15(11):1427-1435. PubMed ID: 34590937
[TBL] [Abstract][Full Text] [Related]
15. Small cell lung cancer: a slightly less orphan disease after immunotherapy.
Remon J; Aldea M; Besse B; Planchard D; Reck M; Giaccone G; Soria JC
Ann Oncol; 2021 Jun; 32(6):698-709. PubMed ID: 33737119
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy in Advanced Lung Cancer.
Huang J; Reckamp KL
Oncology (Williston Park); 2020 Jul; 34(7):272-279. PubMed ID: 32674216
[TBL] [Abstract][Full Text] [Related]
17. Radiation combined with immune checkpoint inhibitors for unresectable locally advanced non-small cell lung cancer: synergistic mechanisms, current state, challenges, and orientations.
Wu L; Zhang Z; Bai M; Yan Y; Yu J; Xu Y
Cell Commun Signal; 2023 May; 21(1):119. PubMed ID: 37221584
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant Versus Adjuvant Systemic Therapy for Early-Stage Non-Small Cell Lung Cancer: The Changing Landscape Due to Immunotherapy.
John AO; Ramnath N
Oncologist; 2023 Sep; 28(9):752-764. PubMed ID: 37338126
[TBL] [Abstract][Full Text] [Related]
19. Emerging immune checkpoint inhibitors for the treatment of non-small cell lung cancer.
Bote H; Mesas A; Baena J; Herrera M; Paz-Ares L
Expert Opin Emerg Drugs; 2022 Sep; 27(3):289-300. PubMed ID: 36203360
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapy for Lung Cancer-Improving Outcomes in Patients With Locally Advanced Non-Small Cell Lung Cancer With Immunotherapy.
Sun L; Aggarwal C
Cancer J; 2020; 26(6):548-554. PubMed ID: 33298727
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
